Results 171 to 180 of about 447,481 (255)

Onco-hypertension: hypertension induced by VEGF pathway inhibition. [PDF]

Front Cardiovasc Med
Palaskas NL, Kim JH, Moreno SFL, Casso-Chapa B, Beinart NI, Nnanna N, Mendoza KCO, Deswal A, Yusuf SW, Koutroumpakis E, Abe JI, Ewer MS.   +11 more
europepmc   +1 more source

Paraborg: Paramedic Cyborg Insects for In Situ Emergency Drug‐Delivery

Advanced Science, EarlyView.
This work introduces Paraborg, a human‐supervised paramedic cyborg‐insect platform that combines controllable locomotion, onboard imaging, and an auto‐injection mechanism for in situ drug‐delivery. By demonstrating reliable navigation, target stabilization, injector launch, and multi‐insect teamwork, the study extends cyborg insects from survivor ...
H. Nhan Le, P. Thien Phan, Lachlan Fitzgerald, P. Ross McAree, T. Nho Do, T. Thang Vo‐Doan   +5 more
wiley   +1 more source

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications. [PDF]

Drugs Context
Manunta M, Bruno GM, Ferrantelli A, Ramirez RF, Nardi F.   +4 more
europepmc   +1 more source

Copper‐Doped Prussian Blue Nanozymes With Hyaluronic Acid‐Mediated Targeting Alleviate Oxidative Stress and Regulate Cholesterol Handling for Atherosclerosis Therapy

Advanced Science, EarlyView.
CuPB@HA is a CD44‐associated, plaque‐targeted nanozyme that alleviates oxidative stress, inflammation, and lipid accumulation in macrophages. By reducing CD36‐dependent lipid uptake and promoting ABCA1/ABCG1‐mediated cholesterol handling, it improves macrophage function, preferentially accumulates in atherosclerotic lesions, reduces plaque burden, and ...
Jianliang Ou, Ruihua Ji, Qinglu Zang, Mingkang Wang, Lingling Zhou, Yingliang Wei, Di Yang, Yue Wu, Hongxu Zhu, Jianrong Wu, Xiaojun Cai, Wenxian Du, Junjie Cheng, An Zeng, Yuehua Li   +14 more
wiley   +1 more source

Identification of drug-related cardiovascular risks: A comprehensive analysis using the FAERS database (2004-2024). [PDF]

PLoS One
Qin N, Gan Y, Ouyang J, Qin J, Tang Y, Wu H, Wei S, Wang H, Huang J.   +8 more
europepmc   +1 more source

Engineered Brain‐Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke

Advanced Science, EarlyView.
ABSTRACT Diabetic stroke is characterized by a hyperglycemic and pro‐inflammatory microenvironment that exacerbates neurovascular dysfunction. However, the blood–brain barrier (BBB) remains a formidable obstacle, restricting the delivery of most therapeutic molecules.
Bixin Shen, Chengxiang Zhang, Junhui Wang, Xichong Zhong, Shihao Chen, Xue Wang, Xiaokun Li, Li Lin   +7 more
wiley   +1 more source

Recent Advances in Understanding the Mechanisms of Therapy-Related Cardiovascular Events in Pediatric Hematologic Malignancies. [PDF]

Rev Cardiovasc Med
He W, Feng J, Luo R, Jiang F, Sui X, Hong X.   +5 more
europepmc   +1 more source

[Cardiovascular agents in pregnancy].

Arquivos brasileiros de cardiologia, 1989
A C, Lopes, E E, Martinez Filho, D R, Sustovich   +2 more
openaire   +1 more source

Plaque‐Hepatic Targeting Nanotherapy Disrupts the PCSK9‐LOX‐1 Axis to Suppress oxLDL in Atherosclerosis

Advanced Science, EarlyView.
Self‑amplifying PCSK9–LOX‑1 feedback axis drives atherosclerotic progression by promoting oxLDL generation and endothelial uptake. A dual‑targeting nanoplatform (siPCSK9@PEAL NPs‑aL) is constructed to simultaneously silence hepatic PCSK9 for lipid lowering and block plaque LOX‑1 for anti‑inflammation.
Yi Duan, Yijie Qiu, Yan Zhu, Quan Wang, Jiangtao Lin, Yourong Duan, Qi Wang, Yi Dong   +7 more
wiley   +1 more source

Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors. [PDF]

Front Cardiovasc Med
Umanath K, Dwyer JP, Mentz RJ.
europepmc   +1 more source